From Funder to Founder in Life Sciences AI
In this episode of the Driving the Business of Science podcast, host Keith Parent, CEO of Court Square Group, discusses the intersection of venture capital (VC) and AI in the life sciences industry with Aneesha Raghunathan, Co-founder and CEO of Rightview. Aneesha shares her background in VC and her transition to building AI solutions for life sciences. They discuss the evolution from paper-based to electronic systems, the impact of COVID-19 on investment trends, and the potential of AI in document generation and reconciliation. Aneesha emphasizes the need for AI to enhance quality and efficiency in life sciences, moving from manual reconciliation to real-time error detection. The conversation highlights the importance of AI in improving regulatory compliance and operational efficiency.
Listen on your favorite podcast platforms
iHeart Radio | Apple Podcasts | Spotify | Amazon Music | Buzzsprout
Guest Profile – Aneesha Raghunathan, Co-Founder, CEO, Rightview
Aneesha is co-founder and CEO of Rightview, which helps innovative life sciences orgs streamline drug development ops. Prior to starting the company, she spent 11 years investing in life sciences technology. Most recently, she led that practice at a $4B growth equity fund, where she backed software companies that biopharma, sites, and CROs use to run their operations. She currently also sits on the board of ZenQMS, a life sciences focused quality management technology company.
Introduction and Overview of Court Square Group
- Keith Parent introduces himself as the CEO of Court Square Group and mentions the podcast’s focus on the business of science.
- Keith highlights the diverse areas in the life science world beyond drug development, including the VC world.
- Keith introduces Aneesha Raghunathan, Co-founder and CEO of Rightview, and provides an overview of Court Square Group’s services, including managed infrastructure for life science companies and the content repository RegDocs365.
- Keith mentions the Life Science Launchpad and the focus on AI-based tools within the content repository.
Aneesha Ragunathan’s Background and Rightview AI
- Aneesha introduces herself as the Co-founder and CEO of Rightview, an AI-focused company in the life sciences space.
- Aneesha shares her background in venture capital, private equity, and leading a practice at a large growth equity firm, where she evaluated various software categories in the life sciences industry.
- Aneesha discusses the transition from paper-based systems to electronic systems in the life sciences industry, highlighting the impact of COVID-19 on this transition.
- Aneesha explains the next wave in the industry, focusing on connecting and making information actionable rather than just storing it.
Transition from Investing to Building Rightview
- Keith and Aneesha discuss the transition from paper-based systems to electronic systems, noting the persistence of paper-based processes in some areas.
- Keith highlights the slow adoption of new technologies in the life sciences industry, especially by large pharma companies.
- Aneesha shares her motivation for leaving the investing side to build Rightview, emphasizing the need for responsible systems in regulated end markets.
- Aneesha discusses the gap in the market for point solutions and the potential of AI to unify innovation and regulatory compliance.
Impact of COVID-19 on Investments and AI Adoption
- Keith and Aneesha discuss the impact of COVID-19 on investments, noting the initial pause in early 2020 followed by a boom in early 2021.
- Aneesha explains how COVID-19 accelerated the adoption of electronic systems, particularly in the RBQM space.
- Keith highlights the push for decentralized clinical trials and patient-reported outcomes during COVID-19.
- Aneesha and Keith discuss the role of AI in document generation and reconciliation, with Aneesha emphasizing the importance of auditing and reconciling documents.
Future of AI in Life Sciences
- Aneesha discusses the potential of AI to shift the focus from document generation to document reconciliation and auditing.
- Keith highlights the need for human involvement in the quality aspect of AI-generated documents.
- Aneesha emphasizes the importance of identifying risks and quality triggers in real-time to improve processes.
- Keith and Aneesha discuss the potential for AI to reduce the time spent on manual reconciliation and improve overall quality in the life sciences industry.
Conclusion and Final Thoughts
- Keith thanks Aneesha for her participation and shares his appreciation for her work in funding and building companies in the life sciences industry.
- Aneesha expresses her enthusiasm for the conversation and highlights the importance of partnering with innovative life sciences companies.
- Keith encourages companies to embrace AI and AI-based tools to improve efficiency and quality in their processes.
- The podcast concludes with Keith thanking the audience and expressing his hope for the future of AI in the life sciences industry.
Episode FAQs
How is AI transforming life sciences and drug development?
AI is helping life sciences organizations analyze information, automate repetitive tasks, identify risks, and improve decision-making across clinical development, manufacturing, quality, and post-market activities. The next phase of adoption goes beyond storing documents electronically by connecting information and making it actionable in real time.
How can AI improve regulatory document generation and reconciliation?
AI can assist with drafting documents, comparing information across multiple sources, identifying inconsistencies, and flagging missing or conflicting data. Automating these reconciliation activities can reduce manual review time while enabling quality teams to focus on higher-risk issues that require expert judgment.
Can AI help pharmaceutical and biotech companies improve regulatory compliance?
AI can support compliance by detecting errors earlier, monitoring quality indicators, and creating more consistent processes for reviewing regulated information. However, organizations must validate AI for its intended use, document how it performs, assess risk, and maintain appropriate controls when AI-generated information supports regulatory decisions.
Why is human oversight important when using AI in life sciences?
Human oversight helps ensure that AI-generated content and recommendations are accurate, complete, explainable, and appropriate for their intended purpose. A human-in-the-loop approach allows qualified professionals to review exceptions, evaluate quality concerns, and make final decisions in regulated workflows.
What makes a life sciences AI company attractive to investors?
Investors typically look for solutions that address a significant industry problem, fit naturally into existing workflows, demonstrate measurable improvements in quality or efficiency, and can operate responsibly in regulated environments. The strongest opportunities often move organizations beyond isolated point solutions by connecting information, detecting problems earlier, and supporting both innovation and compliance.